Somewhat Positive Media Coverage Somewhat Unlikely to Affect Editas Medicine (EDIT) Stock Price

Headlines about Editas Medicine (NASDAQ:EDIT) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Editas Medicine earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.2455572109696 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news headlines that may have effected Accern’s rankings:

Editas Medicine (NASDAQ:EDIT) opened at $26.71 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 10.12 and a current ratio of 10.12. Editas Medicine has a 52-week low of $13.12 and a 52-week high of $31.81.

Editas Medicine (NASDAQ:EDIT) last released its earnings results on Tuesday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Editas Medicine had a negative return on equity of 70.19% and a negative net margin of 1,127.03%. The company had revenue of $6.28 million for the quarter, compared to the consensus estimate of $2.66 million. During the same quarter in the previous year, the company posted ($0.59) EPS. The business’s revenue was up 553.0% on a year-over-year basis. analysts anticipate that Editas Medicine will post -2.92 earnings per share for the current fiscal year.

A number of research analysts have issued reports on the company. Morgan Stanley reissued an “equal weight” rating and issued a $28.00 target price (up from $27.00) on shares of Editas Medicine in a research note on Friday, October 6th. ValuEngine raised Editas Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. BidaskClub cut Editas Medicine from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Cann reaffirmed a “hold” rating on shares of Editas Medicine in a research report on Tuesday, November 7th. Finally, Zacks Investment Research cut Editas Medicine from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $26.73.

In other Editas Medicine news, CFO Andrew A. F. Hack sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $24.31, for a total value of $121,550.00. Following the sale, the chief financial officer now owns 5,000 shares in the company, valued at $121,550. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Katrine Bosley sold 8,333 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $24.78, for a total value of $206,491.74. The disclosure for this sale can be found here. Insiders have sold 54,648 shares of company stock worth $1,383,861 in the last quarter. 19.40% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This article was reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit